Francis DiGiovanna's questions to Crinetics Pharmaceuticals Inc (CRNX) leadership • Q1 2025
Question
Francis DiGiovanna, on for Tyler Van Buren, asked for the rationale behind studying morning dosing versus evening dosing in the fourth cohort of the atumelnant trial.
Answer
Dr. R. Struthers, CEO, explained the goal was to explore future optionality for patient convenience. He added that it is important to understand the drug's effect in relation to the strong diurnal rhythm of the HPA axis in CAH patients to ensure timing does not significantly impact efficacy.